A Look At Pfizer (NYSE:PFE) Valuation After Q1 2026 Beat And Pipeline Progress

Pfizer (PFE) is back in focus after reporting first quarter 2026 results that topped analyst expectations, reaffirmed its ...
Seeking Alpha

Pfizer Looks Like A Great Play At Current Valuations

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers. The company leads its peer group in EBITDA and revenue growth, ...
AOL

Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...
Nasdaq

Pfizer: Value Play or Past Its Prime?

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...
Morningstar

Pfizer Earnings: Maintaining Our Valuation as Management Pressed for Evidence of Productivity

Pfizer PFE reported stronger third-quarter results than we anticipated, largely due to significantly higher sales of covid-19 treatment Paxlovid, which also drove management to increase its top- and ...
Morningstar

Pfizer Earnings: In-Line Quarter Despite Covid Product Weakness as Metsera Drama Intensifies

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...